Stereotaxis Secures $50 Million in Funding Through Sales Agreement with Roth Capital

Stereotaxis has entered a sales agreement with Roth Capital for $50 million in common stock. The company designs and manufactures robotic systems, instruments, and information systems for interventional laboratories. Its proprietary technology, Robotic Magnetic Navigation, allows for precise control over interventional catheters and devices. The agreement will help the company expand its products and services.

Stereotaxis (NYSE: STXS), a leading provider of surgical robotics for minimally invasive endovascular intervention, has entered a sales agreement with Roth Capital, securing $50 million in common stock. This investment will support the company's expansion and development of its innovative products and services.

Stereotaxis specializes in Robotic Magnetic Navigation, a proprietary technology that enables precise control over interventional catheters and devices. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere [1].

The agreement with Roth Capital will provide Stereotaxis with the necessary capital to enhance its product offerings and services. This funding will also facilitate the company's mission to improve patient care through robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room.

The company will continue to showcase its technology at the upcoming HRX digital health conference from September 4-6, 2025, in Atlanta. CEO David Fischel will participate in a roundtable discussion on September 5th at 3:45 PM EDT, followed by a panel of electrophysiologists leading a session titled "Cutting-Edge Ablation Techniques That Challenge Traditional Methods and Improve Patient Outcomes" [1].

References:
[1] https://www.stocktitan.net/news/STXS/stereotaxis-technology-to-be-featured-at-heart-rhythm-society-s-hrx-gpgfuvn066ta.html